PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SANA vs. RARE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SANA and RARE is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

SANA vs. RARE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-47.60%
-21.61%
SANA
RARE

Key characteristics

Sharpe Ratio

SANA:

-0.35

RARE:

-0.22

Sortino Ratio

SANA:

0.02

RARE:

-0.05

Omega Ratio

SANA:

1.00

RARE:

0.99

Calmar Ratio

SANA:

-0.67

RARE:

-0.12

Martin Ratio

SANA:

-1.16

RARE:

-0.49

Ulcer Index

SANA:

55.60%

RARE:

18.46%

Daily Std Dev

SANA:

184.47%

RARE:

40.69%

Max Drawdown

SANA:

-96.32%

RARE:

-82.11%

Current Drawdown

SANA:

-92.97%

RARE:

-74.93%

Fundamentals

Market Cap

SANA:

$689.90M

RARE:

$4.09B

EPS

SANA:

-$1.40

RARE:

-$6.29

Total Revenue (TTM)

SANA:

$0.00

RARE:

$395.35M

Gross Profit (TTM)

SANA:

-$7.64M

RARE:

$317.81M

EBITDA (TTM)

SANA:

-$207.59M

RARE:

-$360.20M

Returns By Period

In the year-to-date period, SANA achieves a 87.73% return, which is significantly higher than RARE's 5.73% return.


SANA

YTD

87.73%

1M

4.79%

6M

-46.41%

1Y

-61.70%

5Y*

N/A

10Y*

N/A

RARE

YTD

5.73%

1M

7.75%

6M

-21.08%

1Y

-7.68%

5Y*

-5.64%

10Y*

-2.23%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SANA vs. RARE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SANA
The Risk-Adjusted Performance Rank of SANA is 2424
Overall Rank
The Sharpe Ratio Rank of SANA is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of SANA is 3333
Sortino Ratio Rank
The Omega Ratio Rank of SANA is 3232
Omega Ratio Rank
The Calmar Ratio Rank of SANA is 99
Calmar Ratio Rank
The Martin Ratio Rank of SANA is 1717
Martin Ratio Rank

RARE
The Risk-Adjusted Performance Rank of RARE is 3434
Overall Rank
The Sharpe Ratio Rank of RARE is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of RARE is 3131
Sortino Ratio Rank
The Omega Ratio Rank of RARE is 3131
Omega Ratio Rank
The Calmar Ratio Rank of RARE is 3939
Calmar Ratio Rank
The Martin Ratio Rank of RARE is 3737
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SANA vs. RARE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SANA, currently valued at -0.35, compared to the broader market-2.000.002.00-0.35-0.22
The chart of Sortino ratio for SANA, currently valued at 0.02, compared to the broader market-4.00-2.000.002.004.006.000.02-0.05
The chart of Omega ratio for SANA, currently valued at 1.00, compared to the broader market0.501.001.502.001.000.99
The chart of Calmar ratio for SANA, currently valued at -0.67, compared to the broader market0.002.004.006.00-0.67-0.12
The chart of Martin ratio for SANA, currently valued at -1.16, compared to the broader market-10.000.0010.0020.0030.00-1.16-0.49
SANA
RARE

The current SANA Sharpe Ratio is -0.35, which is lower than the RARE Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of SANA and RARE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50SeptemberOctoberNovemberDecember2025February
-0.35
-0.22
SANA
RARE

Dividends

SANA vs. RARE - Dividend Comparison

Neither SANA nor RARE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SANA vs. RARE - Drawdown Comparison

The maximum SANA drawdown since its inception was -96.32%, which is greater than RARE's maximum drawdown of -82.11%. Use the drawdown chart below to compare losses from any high point for SANA and RARE. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%SeptemberOctoberNovemberDecember2025February
-92.97%
-73.48%
SANA
RARE

Volatility

SANA vs. RARE - Volatility Comparison

Sana Biotechnology, Inc. (SANA) has a higher volatility of 30.23% compared to Ultragenyx Pharmaceutical Inc. (RARE) at 9.38%. This indicates that SANA's price experiences larger fluctuations and is considered to be riskier than RARE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
30.23%
9.38%
SANA
RARE

Financials

SANA vs. RARE - Financials Comparison

This section allows you to compare key financial metrics between Sana Biotechnology, Inc. and Ultragenyx Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab